FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
Peer review, registries, and evidence-based patient information have taken a hit in Trump’s first 100 days in office.
